Physician profile
Michael Daugherty
NPI 1467447938
$9,727.48
in general payments reported to CMS, 2019-2025
36 companies · $382 in 2025
The $382 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,309 · 2020: $1,156 · 2021: $1,932 · 2022: $3,750 · 2023: $853 · 2024: $346 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,580.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,603.34 | 2021-2023 | Interstim |
| Astellas Pharma US INC | $902.05 | 2019-2025 | Xtandi, Myrbetriq |
| Pfizer INC. | $606.49 | 2019-2025 | |
| Boston Scientific Corporation | $567.23 | 2019-2025 | Versapulse Powersuite 100w, Ams 700 Cxr Rte Kit |
| Medtronic USA, INC. | $508.41 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $472.57 | 2019-2023 | Provenge |
| Axonics, INC. | $392.12 | 2020-2023 | Bulkamid |
| Myovant Sciences INC. | $339.64 | 2021-2022 | |
| Janssen Biotech, INC. | $308.07 | 2019-2023 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $297.81 | 2020-2023 | |
| Antares Pharma, INC. | $242.71 | 2020-2023 | Xyosted, Tlando, Nocdurna |
| Sumitomo Pharma America, INC. | $241.19 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $200.02 | 2019-2023 | Botox |
| Merck Sharp & Dohme LLC | $196.64 | 2021-2022 | |
| Urogen Pharma, INC. | $187.56 | 2021-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $181.09 | 2019-2024 | Xiaflex, Aveed |
| Coloplast Corp | $174.03 | 2020-2025 | Titan |
| Teleflex LLC | $173.89 | 2024-2025 | Urolift |
| Allergan, INC. | $172.52 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $165.74 | 2021-2022 | |
| Urovant Sciences INC | $147.12 | 2022 | |
| Amgen INC. | $137.40 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $98.18 | 2023-2025 | Prolaris |
| Dentsply Ih Ab | $84.61 | 2023-2025 | Lofric, Lofric |
| Ferring Pharmaceuticals INC. | $80.22 | 2019 | |
| Sun Pharmaceutical Industries INC. | $51.89 | 2021-2022 | |
| Abc Home Medical Supply, INC. | $41.45 | 2025 | |
| Procept Biorobotics Corporation | $29.64 | 2023 | Aquabeam Robotic System |
| Tolmar Pharmaceuticals, INC. | $26.11 | 2019 | |
| Endo USA, INC. | $24.98 | 2024 | Xiaflex |
| Cook Medical LLC | $13.92 | 2023 | Fiber Dust |
| Acerus Pharmaceuticals Corporation | $13.66 | 2022 | |
| Rochester Medical Corporation | $12.35 | 2019 | |
| Neotract INC. | $11.40 | 2020 | |
| C. R. Bard, INC. & Subsidiaries | $11.13 | 2019 | |
| Clovis Oncology, INC. | $10.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Daugherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.